According to a 2021 study published in the journal Nature Medicine, the 1-year survival of mesothelioma patients who remained cancer-free following targeted therapy treatment was 18.2%.
All of the mesothelioma patients in this study were treated with the targeted therapy drug durvalumab and chemotherapy, and were unable to get surgery.